Snapdragon Chemistry’s main focus is to deliver value to our clients. Thus, we have partnered with trusted, cutting-edge organizations that complement our skill sets and services, to provide the best solutions to our clients.
Johnson Matthey is a global leader in science that enables cleaner air, improved health and more efficient use of natural resources. JM has an extensive offering in clinical to commercial API development and manufacturing, which includes considerable quality systems infrastructure.
Our collaboration with JM creates a complete and powerful end-to-end offering that can provide the full scope of process development and manufacturing services, from flow chemistry route conception to cGMP bulk production. Snapdragon Chemistry and JM have co-located facilities in the Boston area, allowing joint Snapdragon Chemistry and JM teams to interact closely to both develop flow chemistry processes and scale those processes through to manufacturing. This will allow clients to take full advantage of continuous manufacturing technology throughout the drug development life cycle.
Zaiput Flow Technologies
Zaiput Flow Technologies is dedicated to bringing innovative tools for continuous flow to the market. Zaiput specializes in modular liquid-liquid separators and back pressure regulators for a variety of flow rates and with robust designs for harsh chemistries.
Through our partnership with Zaiput Flow Technologies, we will bring the most innovative and effective continuous flow technology to our clients. Zaiput and Snapdragon Chemistry are co-located in the Boston area, enabling us to collaborate efficiently to build cutting-edge reactor systems for continuous flow synthesis.
Paraza Pharma, Inc
Paraza Pharma, Inc. is an innovative company with an aim to improve significantly the efficiency of the drug discovery process from lead identification through lead optimization to development candidates.
Paraza complements Snapdragon Chemistry’s expertise in drug discovery and enables us to provide more holistic, innovative solutions to our clients in the discovery and early development space. Our combined insights, experience, and workforce help power an integrated solution that can completely transform productivity in discovery.
Usher III Initiative
The Usher III Initiative is a non-profit organization dedicated to finding therapies for patients with Usher syndrome type III, a rare genetic disorder that causes the progressive loss of both hearing and sight. Although typically born with normal vision and hearing, by mid-life, those afflicted with this devastating orphan disease are profoundly deaf and legally blind. For the past 17 years, the Initiative has focused on collaborative, therapy-directed, academic and industry research projects to investigate the cause of and a cure for Usher III. Through these efforts, the Initiative has discovered a proprietary compound, currently being manufactured in partnership with Snapdragon Chemistry, which will be developed as a potential treatment. With Snapdragon’s help, the Initiative is closer than ever to achieving its goal!